贝伐单抗对复发性多形性胶质母细胞瘤病例中 99mTc-HYNIC-PSMA-11 摄取的早期影响。
Early Impact of Bevacizumab on the 99mTc-HYNIC-PSMA-11 Uptake in a Case of Recurrent Glioblastoma Multiforme.
发表日期：2024 Aug 28
作者：
Tahereh Ghaedian, Abdolmajid Alipour, Abbas Rakhsha, Hamid Nasrollahi, Arash Saffarian
来源：
CLINICAL NUCLEAR MEDICINE
摘要：
多形性胶质母细胞瘤 (GBM) 是一种高度血管化的肿瘤，据报道前列腺特异性膜抗原 (PSMA) 高表达。另一方面，贝伐珠单抗作为抗血管生成药物越来越多地用于治疗GBM复发。我们提出了一个 GBM 复发病例，在间隔 2 周给予 2 剂贝伐单抗后 1 周，她的肿瘤中 99mTc-HYNIC-PSMA-11 的摄取显着减少。该病例强调了 GBM 继发于血管生成的 PSMA 摄取的主要机制，也暗示了贝伐珠单抗与 PSMA 摄取的潜在相互作用，在 GBM 中 PSMA 放射性示踪剂的诊断和治疗应用期间应特别考虑这一相互作用。版权所有 © 2024 Wolters Kluwer Health, Inc.版权所有。
Glioblastoma multiforme (GBM) is a highly vascularized tumor with reported high prostate-specific membrane antigen (PSMA) expression. On the other hand, bevacizumab as an antiangiogenesis drug is increasingly used in the treatment of GBM recurrence. We present a case of GBM recurrence with significant reduction of 99mTc-HYNIC-PSMA-11 uptake in her tumor 1 week after administration of 2 doses of bevacizumab with 2 weeks' interval. This case emphasizes the main mechanism of PSMA uptake in GBM secondary to angiogenesis and also implies a potential interaction of bevacizumab with PSMA uptake that should be especially considered during diagnostic and therapeutic application of PSMA radiotracers in GBM.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.